Dave founded Iksuda in 2012, now a clinical stage company which is focussed on the development of 1st/best in class ADCs by deploying a toolbox of chemistry and payload approaches to address the challenges of haematological and solid cancers. Iksuda’s operations in Newcastle, UK (Corporate HQ and Research) and Boston, US (Development) are committed to driving the differentiation of ADC therapies through innovation.

The Company is actively recruiting patients for Ph1 trials for its IKS014 (Anti-Her2; completed dose escalation) and IKS03 (anti-CD19) programs and it currently progressing a third, IKS04 a first in class, Anti-CA242 ADC for the treatment of GI cancers through IND enabling studies anticipating initiation of Ph1 clinical trials in Q4 2025.

Prior to Iksuda, Dave led Actavis’s biosimilar programmes and started his industrial career by joining Cobra Biologics before moving to Eden Biodesign, where he led its process development capabilities prior to its acquisition by Watson Pharma.

In addition, Dave holds several NED positions and advises several biotech companies, investment groups and provides local support to Newcastle University’s MRC Confidence in Concept Fund